- Home
- MGNI vs LGND Comparison
MGNI vs LGND Comparison
Compare MGNI & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- LGND
- Stock Information
- Founded
- MGNI 2007
- LGND 1987
- Country
- MGNI United States
- LGND United States
- Employees
- MGNI N/A
- LGND N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- LGND Health Care
- Exchange
- MGNI Nasdaq
- LGND Nasdaq
- Market Cap
- MGNI 2.4B
- LGND 2.0B
- IPO Year
- MGNI N/A
- LGND 1992
- Fundamental
- Price
- MGNI $18.72
- LGND $114.07
- Analyst Decision
- MGNI Strong Buy
- LGND Strong Buy
- Analyst Count
- MGNI 13
- LGND 8
- Target Price
- MGNI $19.23
- LGND $144.71
- AVG Volume (30 Days)
- MGNI 2.0M
- LGND 124.8K
- Earning Date
- MGNI 08-06-2025
- LGND 08-05-2025
- Dividend Yield
- MGNI N/A
- LGND N/A
- EPS Growth
- MGNI N/A
- LGND N/A
- EPS
- MGNI 0.21
- LGND N/A
- Revenue
- MGNI $674,622,000.00
- LGND $181,488,000.00
- Revenue This Year
- MGNI $0.32
- LGND $18.41
- Revenue Next Year
- MGNI $11.02
- LGND $18.87
- P/E Ratio
- MGNI $87.31
- LGND N/A
- Revenue Growth
- MGNI 5.59
- LGND 53.40
- 52 Week Low
- MGNI $8.22
- LGND $77.53
- 52 Week High
- MGNI $21.29
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- MGNI 69.84
- LGND 62.44
- Support Level
- MGNI $16.99
- LGND $111.88
- Resistance Level
- MGNI $18.63
- LGND $116.16
- Average True Range (ATR)
- MGNI 0.62
- LGND 3.58
- MACD
- MGNI 0.03
- LGND 0.89
- Stochastic Oscillator
- MGNI 80.91
- LGND 85.19
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.